St. Jude Medical, Inc. (STJ) Reports Mostly Inline Q2 Results; Guides Q3, FY11 EPS
Tweet
Share
E-mailGet Alerts STJ Hot Sheet
Price: $80.82 --0%
Financial Fact:
Selling, general and administrative expense: 481M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Selling, general and administrative expense: 481M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
St. Jude Medical, Inc. (NYSE: STJ) reported Q2 EPS of $0.85, $0.01 better than the analyst estimate of $0.84. Revenue for the quarter came in at $1.45 billion versus the consensus estimate of $1.45 billion.
Sees Q3 2011 EPS of $0.74-$0.76, versus the consensus of $0.80.
Sees FY2011 EPS of $3.25-$3.30, versus the consensus of $3.30.
Sees Q3 2011 EPS of $0.74-$0.76, versus the consensus of $0.80.
Sees FY2011 EPS of $3.25-$3.30, versus the consensus of $3.30.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
- 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
